Skip to main content
OpenTrials
Completed

NCT Number: NCT03981198

Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite

Feasibility study is to evaluate the safety, tolerability and efficacy of Soliton's Rapid Acoustic Pulse (RAP) device for the treatment of cellulite

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

SkinCare Physicians

Chestnut Hill, Massachusetts, 02467, United States

About this study

To assess the safety and tolerability of Soliton's RAP Nov Heavy for the treatment of cellulite. To assess the efficacy of Soliton's RAP Nov Heavy device for the temporary improvement in appearance of cellulite in terms of mean change in cellulite severity score (CSS).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female ages 18-65 years
  • Participant seeking treatment of cellulite in the upper lateral thigh areas
  • Participant presenting with cellulite Grade I or II on both thighs as graded using the Nurnberger-Muller scale classification (Appendix A)
  • Participant has stable weight. Body Mass Index (B.M.I.) is ≤ 30
  • Participant will not have any other cellulite treatments for 12 months before and throughout the 3-month follow-up
  • Participant is willing to participate in study and adhere to follow-up schedule
  • Participant is able to read and comprehend English
  • Participant has completed Informed Consent Form

Exclusion criteria

  • Participant is pregnant or planning to become pregnant during the duration of the study
  • Participant has a BMI > 30
  • Greater than 10% increase or decrease in body weight within past 6 months
  • Cellulite treatment on the thighs or buttocks in the last 12 months (Topical or non-invasive procedure)
  • Metal or plastic implants in the area of the treatment (vascular stent, or implants in the hips, knees, etc.)
  • Active electronic implants such as pacemakers, defibrillators, cochlear implants, nerve/brain stimulators, drug pump, etc.
  • Prior liposuction in the thighs or buttocks or any other invasive procedure to limit cellulite.
  • Medical disorder that would hinder the wound healing or immune response (no blood disorder, diabetes, inflammatory disease, etc.)

Treatment and study plan

Soliton Rapid Acoustic Pulse (RAP)

Device

Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.

Other names: RAP

Primary outcomes

  1. Incidence of SAEs

    Time frame: 18 weeks

    The primary safety endpoint will be met if all treated Participants are free from serious adverse events (SAEs) attributable to the RAP device immediately post treatment and at the 3-month follow-up visit.

  2. Treatment Tolerability

    Time frame: 18 Weeks

    The primary endpoint will be met if a mean tolerability measure using pain scores averaged across all treated Participants is < 8.0

Secondary outcomes

  1. Cellulite improvement

    Time frame: 18 weeks

    A ≥15% mean reduction in the 0-5-point Cellulite Severity Scale as determined by physician assessment of Participant photographs taken before and 3 months after treatment.

Sponsors and collaborators

Lead sponsor

Soliton

Industry

Registry information

Official study title

Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) Nov Heavy Device for the Treatment of Cellulite

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 10, 2019
Registry last updated
Sep 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.